Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 1,806 Shares

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the transaction, the insider directly owned 37,648 shares in the company, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Alexander Smith also recently made the following trade(s):

• On Wednesday, June 3rd, Michael Alexander Smith sold 2,159 shares of Insmed stock. The shares were sold at an average price of $102.27, for a total value of $220,800.93.
• On Friday, May 22nd, Michael Alexander Smith sold 6,149 shares of Insmed stock. The shares were sold at an average price of $108.47, for a total value of $666,982.03.
• On Monday, March 30th, Michael Alexander Smith sold 19,638 shares of Insmed stock. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24.

Insmed Stock Performance

Shares of INSM opened at $103.44 on Thursday. The stock has a market capitalization of $22.42 billion, a PE ratio of -17.99 and a beta of 0.79. The business’s fifty day moving average price is $114.74 and its 200 day moving average price is $144.81. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm’s revenue for the quarter was up 229.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.42) earnings per share. Equities research analysts forecast that Insmed, Inc. will post -2.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a report on Monday, June 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, June 10th. Mizuho set a $192.00 price target on Insmed in a research report on Tuesday, June 16th. Raymond James Financial initiated coverage on Insmed in a report on Friday, April 10th. They issued an “outperform” rating and a $200.00 price target on the stock. Finally, Barclays boosted their price objective on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research report on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of INSM. Empowered Funds LLC raised its holdings in shares of Insmed by 32.6% during the first quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock valued at $8,501,000 after buying an additional 12,775 shares during the last quarter. Defilade Capital Management L.P. grew its holdings in Insmed by 289.8% in the 1st quarter. Defilade Capital Management L.P. now owns 194,909 shares of the biopharmaceutical company’s stock worth $31,872,000 after buying an additional 144,909 shares in the last quarter. Parallel Advisors LLC increased its position in Insmed by 13.1% in the 1st quarter. Parallel Advisors LLC now owns 2,291 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 266 shares during the period. NewEdge Advisors LLC increased its position in Insmed by 133.0% in the 1st quarter. NewEdge Advisors LLC now owns 6,015 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 3,433 shares during the period. Finally, NWI Management LP raised its stake in Insmed by 2.6% during the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock valued at $165,809,000 after acquiring an additional 25,540 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.